Global Azilsartan Medoxomil API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Azilsartan Medoxomil API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension to lower blood pressure which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used either alone or in combination with other antihypertensive agents such as chlorthalidone (CLD). As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug of azilsartan. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase.
Azilsartan Medoxomil API report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Azilsartan Medoxomil API market is projected to reach US$ 56 million in 2034, increasing from US$ 15 million in 2022, with the CAGR of 20.0% during the period of 2024 to 2034. Demand from 20 mg Tablets and 40 mg Tablets are the major drivers for the industry.
Main manufacturers of global azilsartan medoxomil API market are Takeda, Metrochem API and Jubilant Pharma. Takeda and Metrochem API are the top 2 players and accounts for over 40% of global market share in total. Geographically speaking, USA is the largest market and covers about 30% of total market share, followed by Europe with 20%. In terms of application, 40 mg Tablets holds an important market share of over 50%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Azilsartan Medoxomil API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Takeda
Lupin
Acura Labs
Metrochem API
Jubilant Pharma
Zhejiang Hongyuan
Honour Lab
HEC Pharm
Enomark
CTX Life Sciences
Zhejiang Tianyu
Zhuhai Rundu
Valiant Co
Segment by Type
0.99
Others
20 mg Tablets
40 mg Tablets
80 mg Tablets
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Azilsartan Medoxomil API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Azilsartan Medoxomil API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Azilsartan Medoxomil API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Azilsartan Medoxomil API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Azilsartan Medoxomil API introduction, etc. Azilsartan Medoxomil API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Azilsartan Medoxomil API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Azilsartan Medoxomil API report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Azilsartan Medoxomil API market is projected to reach US$ 56 million in 2034, increasing from US$ 15 million in 2022, with the CAGR of 20.0% during the period of 2024 to 2034. Demand from 20 mg Tablets and 40 mg Tablets are the major drivers for the industry.
Main manufacturers of global azilsartan medoxomil API market are Takeda, Metrochem API and Jubilant Pharma. Takeda and Metrochem API are the top 2 players and accounts for over 40% of global market share in total. Geographically speaking, USA is the largest market and covers about 30% of total market share, followed by Europe with 20%. In terms of application, 40 mg Tablets holds an important market share of over 50%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Azilsartan Medoxomil API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Takeda
Lupin
Acura Labs
Metrochem API
Jubilant Pharma
Zhejiang Hongyuan
Honour Lab
HEC Pharm
Enomark
CTX Life Sciences
Zhejiang Tianyu
Zhuhai Rundu
Valiant Co
Segment by Type
0.99
Others
Segment by Application
20 mg Tablets
40 mg Tablets
80 mg Tablets
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Azilsartan Medoxomil API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Azilsartan Medoxomil API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Azilsartan Medoxomil API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Azilsartan Medoxomil API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Azilsartan Medoxomil API introduction, etc. Azilsartan Medoxomil API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Azilsartan Medoxomil API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices